Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair

Chromosome region maintenance protein 1 (CRM1) mediates protein export from the nucleus and is a new target for anticancer therapeutics. Broader application of KPT-330 (selinexor), a first-in-class CRM1 inhibitor recently approved for relapsed multiple myeloma and diffuse large B-cell lymphoma, have...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Abeykoon, Jithma P., Wu, Xiaosheng, Nowakowski, Kevin E., Dasari, Surendra, Paludo, Jonas, Weroha, S. John, Hu, Chunling, Hou, Xiaonan, Sarkaria, Jann N., Mladek, Ann C., Phillips, Jessica L., Feldman, Andrew L., Ravindran, Aishwarya, King, Rebecca L., Boysen, Justin, Stenson, Mary J., Carr, Ryan M., Manske, Michelle K., Molina, Julian R., Kapoor, Prashant, Parikh, Sameer A., Kumar, Shaji, Robinson, Steven I., Yu, Jia, Boughey, Judy C., Wang, Liewei, Goetz, Matthew P., Couch, Fergus J., Patnaik, Mrinal M., Witzig, Thomas E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2021
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7845010/
https://ncbi.nlm.nih.gov/pubmed/33507295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020009013
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados